Dent Neurologic


Research Study

OXA1 Study

0XA1 Study This study will test if an investigational medicine (a Medicine being studied) could safely reduce weight in people with obesity or overweight. Inclusion Criteria: Aged 18 to 75 years old  Do NOT have diabetes  have obesity (BMI of 30 or more) or have overweight (BMI of 27 or more) and a health condition:

OXA1 Study Read More »


CogMS – A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as

CogMS Read More »

Generation HD-2

Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study:   25 Years to 50 Years   (Adult) Sexes Eligible for Study:   All Generation HD-2 Link

Generation HD-2 Read More »


ENVISION Trial  The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease. What is Alzheimer’s Disease? Alzheimer’s is

ENVISION Read More »


PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a

PROSEEK Read More »

ADNI4 Trial

ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly

ADNI4 Trial Read More »

ADNI3 Trial

ADNI3 Trial Dent is taking part in an observational study called the ADNI3 Trial. This historic study of brain aging could help change the future of Alzheimer’s disease. We are looking for volunteers between 55 and 90 years of age to participate in the ADNI3 trial. Poor memory is often viewed as a simple sign

ADNI3 Trial Read More »

Scroll to Top